A Phase 2, 26 Week, Multicentre, Randomized Double Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy and Safety of Tolterodine, Pregabalin and a Tolterodine-Pregabalin Combination for Idiopathic Overactive Bladder

NCT00746681 Phase 2 COMPLETED

Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	COMPLETED
Enrolment	188
Start date	2005-12
Completion	2006-11

Conditions

• Overactive Bladder

Interventions

• Tolterodine & Pregabalin
• Tolterodine
• Placebo
• Tolterodine & Pregabalin
• Pregabalin

Primary outcomes

• Change in mean voided volume per micturition (from baseline). — 4 weeks

Countries

Czechia, Lithuania, Norway, Slovakia, Sweden, United Kingdom